Patient Outcomes-Focused Highlights from the National Lipid Association’s Clinical Lipid Update

Released On
August 21, 2019

Expires On
August 21, 2020

Media Type

Completion Time
83 minutes

Cardiology, Endocrinology


Scroll to the Bottom of this Information to Begin this Course

This activity is provided by the National Lipid Association.


Supported by an educational grant from Amgen, Esperion Therapeutics, Kowa Pharmaceuticals America, Inc., and Novo Nordisk.


Credit Available

  • Physicians — maximum of 1.50 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 contact hours.
  • Pharmacists — 1.50 contact hours (.15 CEUs) of the Accreditation Council for Pharmacy Education.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses with an interest in lipid management.

Program Overview

This case-based enduring activity will cover the diagnosis, treatment and management of patients with dyslipidemia.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe strategies that improve patient adherence.
  • Apply current guidelines on the diagnosis, management and treatment of high-risk patients.
  • Compare therapeutic options for the treatment of ASCVD risk in patients with diabetes.
  • Define treatment options to minimize microvascular complications related to diabetes.


Kim K. Birtcher, PharmD, CLS, FNLA

Clinical Professor
University of Houston College of Pharmacy
Houston, TX

Lynne T. Braun, PhD, CNP, CLS, FNLA

Professor, Colleges of Nursing and Medicine,
Rush University
Nurse Practitioner,
Rush Heart Center for Women
Rush University Medical Center
Chicago, IL

Leah M. Wilson, MD

Assistant Professor- Endocrinology
Oregon Health & Science University
Portland, OR

Nathan D. Wong, PhD, FNLA

Professor, Medicine
School of Medicine
Director, UCI Heart Disease Prevention Program (Preventive Cardiology)
School of Medicine
Professor, Department of, Epidemiology
School of Medicine
Professor, Genetic Epidemiology Research Institute
Irvine, CA

Accreditation Statement

In support of improving patient care, The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Credit Designation

The National Lipid Association designates this enduring internet activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants Credit Designation

NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Pharmacist Credit Designation

Universal Activity Number JA0007192-0000-19-023-H01-P (Application).
This Activity has been approved for 1.50 contact hour(s) (.15 CEUs) of the Accreditation Council for Pharmacy Education

Nursing Credit Designation

The maximum number of hours awarded for this CE activity is 1.5 contact hours.

Disclosures of Conflicts of Interest

Kim K. Birtcher, PharmD, CLS, FNLA

  • Has nothing to disclose.

Lynne T. Braun, PhD, CNP, CLS, FNLA

  • Author: UpToDate
  • Advisory Board: UpToDate

Leah M. Wilson, MD

  • Has nothing to disclose

Nathan D. Wong, MD, FNLA

  • Contracted Research: Amarin, Amgen, Boehringer Ingelheim, Novo Nordisk
  • Speaker: Sanofi

Staff and Reviewer Disclosures

  • NLA Staff: Has nothing to disclose
  • Kathleen Hawke Byrne, CRNP, BSN, MSN : Advisory Board: Amgen
  • Pamela B. Morris, MD, FNLA : Advisory Board: Amgen, Sanofi/ Regeneron
    Contracted Research: Esperion
  • Scott W. Shurmur, MD, FNLA : Has nothing to disclose

Method of Participation

Statements of credit will be awarded based on the participant’s participation in the activity and post-assessment with a score of 75% or greater and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at The deadline to claim credit is August 21, 2020.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at within 4 weeks.

For any questions regarding credit please contact

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  • Read the CME/CE information and faculty disclosures.
  • Participate in the online activity.
  • Submit the evaluation form to the National Lipid Association.
  • Certificates will be available to print upon completion of the activity.

    Course Viewing Requirements

    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above

    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above.

    Disclosure of Unlabeled Use and Investigational Products

    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclosure Declaration

    It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.


    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.


    The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.